BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/4/2025 7:41:48 AM | Browse: 3 | Download: 14
 |
Received |
|
2024-09-26 13:23 |
|
Peer-Review Started |
|
2024-09-26 13:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-02-19 07:37 |
|
Revised |
|
2025-03-09 14:49 |
|
Second Decision |
|
2025-04-25 02:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-04-25 03:55 |
|
Articles in Press |
|
2025-04-25 03:55 |
|
Publication Fee Transferred |
|
2025-03-11 08:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-05-20 07:29 |
|
Publish the Manuscript Online |
|
2025-06-04 07:41 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kai-Fei Zhao, Chao-Bang Xie and Yang Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yang Wu, Department of Intervention, The second Affiliated Hospital of Zunyi Medical University, Intersection of Xinlong Avenue and Xinpu Avenue in Xinpu New District, Zunyi City, Zunyi 563000, Guizhou Province, China. 1096945853@qq.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Radiomics; Computed tomography; Prognosis; Treatment response |
| Core Tip |
Hepatocellular carcinoma (HCC) is often diagnosed at advanced stages, where transarterial chemoembolization (TACE) serves as a key therapy. However, nearly 50% of patients show poor TACE response due to tumor heterogeneity. This study integrates preoperative computed tomography radiomics and clinical factors to build a predictive model for TACE efficacy. Radiomics noninvasively extracts quantitative imaging features reflecting tumor pathophysiology, enabling precise assessment of treatment response. The combined model stratifies patients by predicted risk, guiding timely transition to alternative therapies (e.g., targeted drugs or immunotherapy) for non-responders. This approach enhances personalized HCC management, optimizes resource allocation, and improves survival outcomes through data-driven clinical decision-making. |
| Publish Date |
2025-06-04 07:41 |
| Citation |
<p>Zhao KF, Xie CB, Wu Y. Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model. <i>World J Clin Cases</i> 2025; 12(23): 101742</p> |
| URL |
https://www.wjgnet.com/2307-8960/full/v13/i23/101742.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v13.i23.101742 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
